Dolutegravir + Lamivudine bulk supplier for pharma manufacturers

Dolutegravir + Lamivudine 50 mg / 300 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 50 mg / 300 mg

Reference Brands: Dovato(EU & US)

Dolutegravir + Lamivudine is a two-drug HIV-1 treatment that combines an integrase inhibitor and an NRTI for effective viral suppression. Marketed as Dovato, it offers once-daily dosing, fewer side effects, and is FDA and EMA approved for treatment-naïve patients.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Dolutegravir + Lamivudine is a fixed-dose combination antiretroviral medication used to treat HIV-1 infection in adults and adolescents. This two-drug regimen combines Dolutegravir, an integrase strand transfer inhibitor (INSTI), and Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI), to effectively suppress viral replication. Marketed under the brand name Dovato, it offers once-daily oral dosing with a simplified regimen, reducing pill burden. Approved by the US FDA and EMA, this dual therapy is recommended for treatment-naïve patients with no resistance to either drug. Dolutegravir + Lamivudine is known for its high efficacy, tolerability, and minimal side effects, supporting long-term HIV manageme

Dolutegravir + Lamivudine — third party manufacturing & bulk supply

Dolutegravir + Lamivudine 50 mg / 300 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Dolutegravir + Lamivudine is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Dolutegravir + Lamivudine listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Dolutegravir + Lamivudine →

Back to Listing

Frequently Asked Questions

Dolutegravir and lamivudine are used together as a complete two-drug regimen for the treatment of HIV-1 infection in adults and adolescents. This combination helps suppress viral replication, maintains viral load control, and reduces pill burden while offering an effective long-term treatment option.

It is made from Dolutegravir, an integrase strand transfer inhibitor, and Lamivudine, a nucleoside reverse transcriptase inhibitor. These two active substances work synergistically to block different stages of the HIV replication cycle.

The trade name for this combination is Dovato.

Dovato is manufactured by ViiV Healthcare.

The generic name is Dolutegravir + Lamivudine.

The brand name is Dovato.

It is manufactured in the UK and Europe by ViiV Healthcare, and licensed generic versions are produced in India by approved pharmaceutical manufacturers for global supply.